|
Clerk of the House of Representatives Legislative Resource Center 135 Cannon Building Washington, DC 20515 http://lobbyingdisclosure.house.gov |
Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510 http://www.senate.gov/lobby |
LOBBYING REGISTRATION
Lobbying Disclosure Act of 1995 (Section 4)
| 1. Effective Date of Registration | 07/16/2009 |
||||
| 2. House Identification | 317480229 |
Senate Identification | 1182-1005522 |
||
REGISTRANT Organization/Lobbying Firm Self Employed Individual
| 3. Registrant | Organization | ALSTON & BIRD LLP |
||||
| Address | THE ATLANTIC BUILDING |
Address2 | 950 F STREET, NW |
| City | WASHINGTON |
State | DC |
Zip | 20004 |
Country | USA |
4. Principal place of business (if different than line 3)
| City | |
State | |
Zip | |
Country | |
| 5. Contact name and telephone number | International Number |
| Contact | Mr. Adam J. Biegel |
Telephone | 2022393692 |
ldafilings@alston.com |
CLIENT A Lobbying Firm is required to file a separate registration for each client. Organizations employing in-house lobbyists should check the box labeled “Self” and proceed to line 10. Self
| 7. Client name | Novo Nordisk Inc. |
| Address | 920 Massachusetts Avenue, N.W. Suite 500 |
| City | Washington |
State | DC |
Zip | 20001 |
Country | USA |
| City | |
State | |
Zip | |
Country | |
LOBBYISTS
10. Name of each individual who has acted or is expected to act as a lobbyist for the client identified on line 7. If any person listed in this section has served as a “covered executive branch official” or “covered legislative branch official” within twenty years of first acting as a lobbyist for the client, state the executive and/or legislative position(s) in which the person served.
| Name | Covered Official Position (if applicable) | ||
First |
Last |
Suffix |
|
| Mark | Rayder | | LA, Rep. Tom Latham; LA, Rep. Rodney Frelinghuysen |
| Mark | Rayder | | District Rep., Rep. Dean Gallo. |
| | | | |
| | | | |
| | | | |
LOBBYING ISSUES
11. General lobbying issue areas (Select all applicable codes).
BUD |
HCR |
MMM |
PHA |
TAX |
|
|
|
|
12. Specific lobbying issues (current and anticipated)
Issues related to health care; the prevention and treatment of diabetes, obesity, hemophilia and growth deficiency; prescriptions drugs; comprehensive tax reform.
AFFILIATED ORGANIZATIONS
13. Is there an entity other than the client that contributes more than $5,000 to the lobbying activities of the registrant in a quarterly period and either participates in and/or in whole or in major part supervises or controls the registrant’s lobbying activities?
| No --> Go to line 14. | Yes --> Complete the rest of this section for each entity matching the criteria above, then proceed to line 14. |
| Internet Address: | |
| Name | Address | Principal Place of Business | ||||||||
| Street | ||||||||||
|
||||||||||
|
|
|
||||||||
|
|
|||||||||
|
|
|
||||||||
|
|
|||||||||
|
|
|
||||||||
|
|
FOREIGN ENTITIES
14. Is there any foreign entity
a) holds at least 20% equitable ownership in the client or any organization identified on line 13; or
b) directly or indirectly, in whole or in major part, plans, supervises, controls, directs, finances or subsidizes activities of the client or any organization identified on line 13; or
c) is an affiliate of the client or any organization identified on line 13 and has a direct interest in the outcome of the lobbying activity?
| No --> Sign and date the registration. | Yes --> Complete the rest of this section for each entity matching the criteria above, then sign the registration. |
| Address | Ownership | |||||
| Name | Street | Principal place of business | Amount of contribution | |||
|
(city and state or country) | for lobbying activities | ||||
Tuborg Havnevej 19 |
|
|||||||||||
Novo Nordisk US, wholly-owned by Novo Nordisk A/S |
|
|
0.00 |
100 |
% | |||||||
Tuborg Havnevej 19 |
|
|||||||||||
Novo A/S (owns 26.5% of NN A/S) |
|
|
0.00 |
26.5 |
% |
| Signature | Digitally Signed By: Adam J. Biegel |
Date | 09/25/2017 |